CN111405913A - 生物活性玻璃组合物和牙本质超敏性修复 - Google Patents
生物活性玻璃组合物和牙本质超敏性修复 Download PDFInfo
- Publication number
- CN111405913A CN111405913A CN201880075910.2A CN201880075910A CN111405913A CN 111405913 A CN111405913 A CN 111405913A CN 201880075910 A CN201880075910 A CN 201880075910A CN 111405913 A CN111405913 A CN 111405913A
- Authority
- CN
- China
- Prior art keywords
- composition
- dental
- bioactive glass
- formulation
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 153
- 239000005313 bioactive glass Substances 0.000 title claims abstract description 48
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 19
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 19
- 230000009610 hypersensitivity Effects 0.000 title claims abstract description 19
- 230000008439 repair process Effects 0.000 title description 2
- 238000009472 formulation Methods 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 25
- 239000000606 toothpaste Substances 0.000 claims description 23
- 210000005239 tubule Anatomy 0.000 claims description 22
- 229940034610 toothpaste Drugs 0.000 claims description 19
- 239000000377 silicon dioxide Substances 0.000 claims description 16
- 229910052681 coesite Inorganic materials 0.000 claims description 15
- 229910052906 cristobalite Inorganic materials 0.000 claims description 15
- 229910052682 stishovite Inorganic materials 0.000 claims description 15
- 229910052905 tridymite Inorganic materials 0.000 claims description 15
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 14
- KKCBUQHMOMHUOY-UHFFFAOYSA-N Na2O Inorganic materials [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 claims description 13
- 229910052593 corundum Inorganic materials 0.000 claims description 12
- 229910001845 yogo sapphire Inorganic materials 0.000 claims description 12
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 9
- 230000000395 remineralizing effect Effects 0.000 claims description 9
- -1 brighteners Substances 0.000 claims description 7
- 239000003205 fragrance Substances 0.000 claims description 7
- 229910001634 calcium fluoride Inorganic materials 0.000 claims description 5
- 239000006072 paste Substances 0.000 claims description 5
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 239000012669 liquid formulation Substances 0.000 claims description 4
- 239000003082 abrasive agent Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- 239000002324 mouth wash Substances 0.000 claims description 3
- 238000005498 polishing Methods 0.000 claims description 3
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 241001122767 Theaceae Species 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 229940051866 mouthwash Drugs 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims 1
- 239000011521 glass Substances 0.000 description 26
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 17
- 210000004268 dentin Anatomy 0.000 description 14
- 239000000306 component Substances 0.000 description 10
- 229940091249 fluoride supplement Drugs 0.000 description 9
- 239000000395 magnesium oxide Substances 0.000 description 9
- 235000012245 magnesium oxide Nutrition 0.000 description 9
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 9
- 230000000975 bioactive effect Effects 0.000 description 8
- 239000013022 formulation composition Substances 0.000 description 8
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229910052586 apatite Inorganic materials 0.000 description 6
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 6
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 229910052587 fluorapatite Inorganic materials 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000002241 glass-ceramic Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000000120 Artificial Saliva Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000002599 Smear Layer Diseases 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- NKCVNYJQLIWBHK-UHFFFAOYSA-N carbonodiperoxoic acid Chemical compound OOC(=O)OO NKCVNYJQLIWBHK-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000586 desensitisation Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229940077441 fluorapatite Drugs 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000004323 potassium nitrate Substances 0.000 description 3
- 235000010333 potassium nitrate Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 3
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 2
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000005385 borate glass Substances 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000005388 borosilicate glass Substances 0.000 description 2
- 230000002925 chemical effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000000551 dentifrice Substances 0.000 description 2
- 201000002170 dentin sensitivity Diseases 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 2
- 239000002966 varnish Substances 0.000 description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- RCSBILYQLVXLJG-UHFFFAOYSA-N 2-Propenyl hexanoate Chemical compound CCCCCC(=O)OCC=C RCSBILYQLVXLJG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229940090898 Desensitizer Drugs 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 241001632427 Radiola Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940095076 benzaldehyde Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- WVMPCBWWBLZKPD-UHFFFAOYSA-N dilithium oxido-[oxido(oxo)silyl]oxy-oxosilane Chemical compound [Li+].[Li+].[O-][Si](=O)O[Si]([O-])=O WVMPCBWWBLZKPD-UHFFFAOYSA-N 0.000 description 1
- 239000006136 disilicate glass ceramic Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940093503 ethyl maltol Drugs 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000006112 glass ceramic composition Substances 0.000 description 1
- 239000000156 glass melt Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- GFAZHVHNLUBROE-UHFFFAOYSA-N hydroxymethyl propionaldehyde Natural products CCC(=O)CO GFAZHVHNLUBROE-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- 125000005524 levulinyl group Chemical group 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000032724 odontogenesis Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C4/00—Compositions for glass with special properties
- C03C4/0007—Compositions for glass with special properties for biologically-compatible glass
- C03C4/0021—Compositions for glass with special properties for biologically-compatible glass for dental use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/20—Protective coatings for natural or artificial teeth, e.g. sealings, dye coatings or varnish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/70—Preparations for dentistry comprising inorganic additives
- A61K6/71—Fillers
- A61K6/77—Glass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
- A61K6/831—Preparations for artificial teeth, for filling teeth or for capping teeth comprising non-metallic elements or compounds thereof, e.g. carbon
- A61K6/836—Glass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
- A61K8/21—Fluorides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/04—Glass compositions containing silica
- C03C3/062—Glass compositions containing silica with less than 40% silica by weight
- C03C3/064—Glass compositions containing silica with less than 40% silica by weight containing boron
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/04—Glass compositions containing silica
- C03C3/076—Glass compositions containing silica with 40% to 90% silica, by weight
- C03C3/097—Glass compositions containing silica with 40% to 90% silica, by weight containing phosphorus, niobium or tantalum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Geochemistry & Mineralogy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Ceramic Engineering (AREA)
- Plastic & Reconstructive Surgery (AREA)
- Cosmetics (AREA)
Abstract
一种牙科制剂,其包含:有效量的如本文所定义的生物活性玻璃组合物;以及有效量的如本文所定义的合适的载剂。还揭示了牙科制剂的制造方法和治疗例如牙本质超敏性的使用方法。
Description
本申请根据35U.S.C.§119,要求2017年11月28日提交的美国临时专利申请第62/591,423号的优先权,其全文通过引用结合入本文。
相关申请的交叉参考
本申请涉及2016年5月25日提交的如下共同拥有和转让的USSN临时申请:
第62/342,384号,题为“BIOACTIVE ALUMINOBORATE GLASSES(生物活性铝硼酸盐玻璃)”;
第62/342,377号,题为“MAGNETIZABLE GLASS CERAMIC COMPOSITION ANDMETHODS THEREOF(可磁化玻璃陶瓷组合物及其方法)”;
第62/342,381号,题为“LITHIUM DISILICATE GLASS-CERAMICCOMPOSITIONS ANDMETHODS THEREOF(二硅酸锂玻璃陶瓷组合物及其方法);”
第62/342,391号,题为“BIODEGRADABLE MICROBEADS(可生物降解微珠粒)”;以及
第62/342,411号,题为“BIOACTIVE GLASS MICROSPHERES(生物活性玻璃微球体)”,但是没有要求它们的优先权。
本申请还涉及2015年7月7日提交的共同拥有和转让的USSN申请第62/189,880号,题为“ANTIMICROBIAL PHASE-SEPARATING GLASS AND GLASS CERAMIC ARTICLES ANDLAMINATES(抗微生物相分离玻璃以及玻璃陶瓷制品和层叠体)”,其提到了具有(释放了铜离子的)可降解相和不可降解相的含铜层叠体,但是没有要求其优先权。
本申请还涉及如下共同拥有且转让的USSN申请:
2017年11月28日提交的第62/591,446号,题为“HIGH LIQUIDUS VISCOSITYBIOACTIVE GLASS(高液相线粘度生物活性玻璃)”;以及
2017年11月28日提交的第62/591,438号,题为“CHEMICALLY STRENGTHENEDBIOACTIVE GLASS-CERAMICS(化学强化生物活性玻璃陶瓷)”;
2017年11月28日提交的第62/591,429号,题为“BIOACTIVE BORATE GLASS ANDMETHODS THEREOF(生物活性硼酸盐玻璃及其方法)”,它们与本申请同时提交,但是本申请没有要求它们的优先权。
本文所述的出版物或专利文献的全文内容分别通过参考结合于本文。
背景技术
本公开内容涉及玻璃组合物、生物活性玻璃组合物,以及该组合物的制造和使用方法。
发明内容
在实施方式中,本公开内容提供了玻璃组合物、生物活性玻璃组合物、生物活性牙科制剂(例如,牙膏),以及组合物的制造和使用方法。
在实施方式中,本公开内容提供了用于治疗牙本质超敏性的组合物和方法。
在实施方式中,本公开内容提供了一组硼酸盐和硼硅酸盐生物活性玻璃,口腔护理产品,例如牙膏、漱口水和类似制剂,用于治疗牙本质超敏性。
在实施方式中,本公开内容提供的玻璃组合物对于暴露牙本质细管的堵塞率明显高于含45S5的牙膏,证实了对于治疗牙本质超敏性的优异性质。
在实施方式中,本公开内容提供了如本文所定义的生物活性玻璃组合物,其包含或者不包含选定的源添加剂。
附图说明
在本公开内容的实施方式中:
图1显示所揭示的生物活性组合物的化学作用和物理作用的假定方案。
图2A至2F显示测试的牙本质盘在用各种制剂治疗1周之后的SEM显微镜图。
图3A至3C显示牙本质沉积物在用含实施例1的牙膏制剂治疗1周之后的SEM-EDS分析。
具体实施方式
下面参考附图(如果有的话)对本公开内容的各个实施方式进行详细描述。参考各个实施方式不限制本发明的范围,本发明的范围仅受所附权利要求书的范围限制。此外,在本说明书中列出的任何实例都不是限制性的,并且仅列出了要求保护的本发明的诸多可能的实施方式中的一些实施方式。
在实施方式中,所揭示的组合物、制品以及制造和使用方法提供了一个或多个优势特征或方面,包括例如,如下文所述。任意权利要求所陈述的特征或方面一般在本发明的所有方面适用。在任一项权利要求中所陈述的任意单个或多个特征或方面可以结合或与任一项或多项其它权利要求中所述的任意其它特征或方面结合或置换。
定义
“牙本质超敏性”(DH)“牙本质敏感性”(DS)或者类似术语指的是由于冷热、空气、触摸或者化学或渗透刺激物(例如甜食)导致的短暂刺痛。
“遮挡”,“堵塞”,“遮蔽”或者类似术语指的是例如封闭或堵塞至阻塞。
“玻璃(glass)”“多个玻璃(glasses)”或者类似术语可以表示玻璃或玻璃陶瓷。
“玻璃制品”或者类似术语可以表示整体或部分由玻璃或玻璃陶瓷制造的任意物体。
“香料”“调味剂”或者类似术语可以表示当用户与组合物接触时,为所公开的组合物提供感官性质的任何天然或合成物质。香料可以是例如单种化合物或者化合物的混合物。可以对香料进行选择,从而给予组合物或产品独特的香味或者维持不同产品批次之间或者配方改变之后的香味一致性。香料可以是任何已知或发现的化合物,例如:二乙酰基,乙酰丙酰基,乙偶姻,乙酸异戊酯,苯甲醛,肉桂醛,丙酸乙酯,邻氨基苯甲酸甲酯,柠檬烯,癸二烯酸乙酯(ethyl decadienoate),己酸烯丙酯,乙基麦芽酚(ethyl maltol),乙基香兰素,水杨酸甲酯,以及类似化合物或其混合物。
本领域技术人员已知的其他典型组合物组分或制剂成分例如研磨剂、湿润剂、着色剂、抗菌剂、表面活性剂、增白剂、粘合剂以及类似组分或成分参见例如en.wikipedia.org/wiki/Toothpaste。
“血管新生能力”、“血管生成”、“血管新生的”或者类似术语指的是从已有血管形成新血管的生理过程。
“包括”、“包含”或类似术语意为包括但不限于,即内含而非排他。
本文所述的实施方式中用来对例如组合物中成分的量、浓度、体积、加工温度、加工时间、产率、流速、压力、粘度和类似数值及其范围或者组件的尺寸以及类似数值及其范围进行修饰的“约”是指可能发生的数值量的改变,例如,源自制备材料、组合物、复合体、浓缩物、组件部件、制品制造或使用制剂所用的常规测量和操作过程;源自这些过程中的偶然性误差;源自用来实施所述方法的起始材料或成分的制造、来源或纯度的差异;以及类似因素。术语“约”还包括由于具有特定初始浓度或混合物的组合物或制剂的老化而不同的量,以及由于混合或加工具有特定初始浓度或混合物的组合物或制剂而不同的量。
“任选的”或“任选地”指的是随后描述的事件或情况可能发生或可能不发生,描述内容包括事件或情况发生的场合以及事件或情况没有发生的场合。
除非另有说明,否则,本文所用的不定冠词“一个”或“一种”及其相应的定冠词“该”表示至少一(个/种),或者一(个/种)或多(个/种)。
可以采用本领域技术人员熟知的缩写(例如,表示小时的“h”或“hrs”;表示克的“g”或“gm”;表示毫升的“mL”;表示室温的“rt”;表示纳米的“nm”以及类似缩写)。
在组分、成分、添加剂、尺寸、条件、时间和类似方面公开的具体和优选的数值及其范围仅用于说明;它们不排除其他限定数值或限定范围内的其他数值。本公开内容的组合物和方法可包括本文所述的任何数值或数值、具体数值、更具体的数值和优选数值的任何组合,包括明示或暗示的中间值和范围。
牙本质超敏性是全球口腔健康问题,并且对于大部分的牙科专业来说,其治疗仍然是明显的问题。牙本质超敏性是由于缺乏牙本质细管的涂抹层所导致的,这使得牙本质细管暴露于热刺激、化学刺激、机械刺激或者渗透刺激。在细管内的流体移动刺激了对流体压力敏感的机械受体,导致刺激传递到牙髓神经并最终引起疼痛反应。通常来说,可以通过例如牙齿神经末梢的化学脱敏,细管闭塞剂或屏障降低牙本质渗透性,或者这两种来治疗牙本质超敏性(参见S.B.Low,“Reduction in dental hypersensitivity with nano-hydroxyapatite,potassium nitrate,sodium monoflurophosphate and antioxidants(用纳米羟基磷灰石、硝酸钾、单氟磷酸钠和抗氧化剂来降低牙科超敏性)”,Open Dent J,2015;(9):92–97;S.Miglani,“Dentin hypersensitivity:Recent trends in management(牙本质超敏性:近期管理趋势)”,J Conserv Dent,2010,13(4):218–224;A.R.Davari,“Dentin hypersensitivity:Etiology,diagnosis and treatment;a literature review(牙本质超敏性:病因、诊断和治疗;文献综述)”,J Dent(Shiraz),2013,14(3):136–145)。使用硝酸钾(KNO3)作为化学脱敏剂可以消除神经细胞膜上的钾离子浓度梯度。因而,神经细胞不会发生去极化并且不会响应刺激(参见上文的S.B.Low)。现有的细管堵塞剂包含:氟化物(即,氟化钙晶体的形成)、草酸盐(即,草酸钙的形成)和氯化锶(即,由于高渗透性以及能够被吸收到有机结缔组织上或者有机结缔组织中与成牙本质细胞上或者成牙本质细胞中过程的可能性,因此对牙本质具有亲和力)(参见上文的S.Miglani)。此外,由于精氨酸和碳酸钙与带负电荷的牙本质表面的粘结,基于精氨酸(Pro-Argin)的牙膏可以形成牙本质状矿物沉淀层(参见R Kulal,“An in-vitro comparison of nano hydroxyapatite,Novamin and Proargin desensitizing toothpastes-a SEMstudy(纳米羟基磷灰石、Novamin和Proargin脱敏牙膏的体外比较-SEM研究)”,J Clin Diagn Res,2016,10(10):ZC51–ZC54)。近来,发现基于硅酸盐玻璃的牙膏(例如,和)(具有例如小于40摩尔%SiO2、大于8摩尔%P2O5)在存在氟化物离子的情况下与唾液反应并释放钙、磷酸根,分别地形成羟基碳酸磷灰石或氟磷灰石(在暴露的牙本质上和在牙本质细管内)(参见上文S.Miglani;L.J.Litkowski,“Compositions containing bioactive glass andtheir use in treating tooth hypersensitivity(含生物活性玻璃的组合物以及他们在治疗牙齿超敏性中的应用)”,US6338751;以及R.Hill,“Bioactive glass composition(生物活性玻璃组合物)”,US 9168272)(还参见H.E.Strassler等人,“DentinalHypersensitivity:Etiology,Diagnosis and Management(牙本质超敏性,病因、诊断与管理)”,Contin.Ed.Pub;以及M.Han等人,“In vivo remineralization of dentin using anagarose hydrogel biomimetic mineralization system(使用琼脂糖水凝胶仿生矿化系统进行牙本质的体内再矿化)”,2017年2月7号,nature.com/srep/)。
相信使用含生物活性玻璃的牙膏进行牙本质处理是可以提供长期保护的唯一治疗方法。不同于其他牙本质细管堵塞试剂,生物活性玻璃会在延长的时间段上永久地可靠缓解牙本质超敏性的疼痛。证实近来开发的铝硼酸盐玻璃具有优异的生物相容性、增强的血管生成,并且可以促进伤口愈合,参见例如上文提到的共同拥有和转让的共同待审专利申请62/342,411和62/342,384。
在实施方式中,本公开内容提供了硼酸盐和硼硅酸盐玻璃组合物阵列,相比于已知的生物活性玻璃,其对于治疗牙本质超敏性具有优异的性质和能力。
在实施方式中,本公开内容提供了例如用于口腔局部应用的牙科制剂,其包含:
有效量(例如,0.1至10重量%)的生物活性玻璃组合物,其包含如下源:
2至70%B2O3,
1至60%SiO2,
2至16%Al2O3,
5至30%CaO,
1至6%P2O5,
1至20%Na2O,
1至20%K2O,以及
1至20%MgO,以组合物总计为100摩尔%计;以及
99.9至90重量%的有效量的合适载剂,以组合物总计为100重量%计。源的摩尔%具有如下等价的重量百分比:1至60%B2O3,1至60%SiO2,2至20%Al2O3,5至25%CaO,1至10%P2O5,1至20%Na2O,1至25%K2O,和1至15%MgO,以组合物总计为100重量%计。
在实施方式中,本公开内容提供了生物活性玻璃,其包含如下源:5至50摩尔%SiO2(4至40重量%),和合适的载剂,其包含如下源:5至25摩尔%SiO2(4至20重量%)(例如,磨料),以组合物总计为100摩尔%(100重量%)计。
在实施方式中,本公开内容提供了牙科制剂组合物,其还包含量为1至25摩尔%(1至30重量%)的氟化物离子源(参见例如US 9168272)。
在实施方式中,本公开内容提供了牙科制剂组合物,其中,氟化物离子源选自例如:NaF、SnF2、CaF2和类似的源,或者选定源的混合物。
在实施方式中,所揭示的生物活性玻璃组合物和含有所揭示的生物活性玻璃组合物的牙科制剂组合物可以基本不含或者完全不含氟化物离子源。
在实施方式中,所揭示的生物活性组合物和含有所揭示的生物活性玻璃组合物的牙科制剂组合物可以基本不含或者完全不含氧化钛源。
在实施方式中,本公开内容提供了牙科制剂组合物(其中,生物活性玻璃组合物是1至20重量%(例如,1至10重量%)的有效量)以及合适的载剂(80至99重量%(例如,90至99重量%)的有效量)。
在实施方式中,本公开内容提供了优选的牙科制剂组合物,其中,生物活性玻璃组合物包含:
40至60%B2O3,
0.1至5%SiO2,
6至10%Al2O3,
15至25%CaO,
1.5至2.0%P2O5,
4至8%Na2O,
6至10%K2O,以及
6至10%MgO,以组合物总计为100摩尔%计。源的摩尔%具有如下等价的重量百分比:30至50%B2O3,0.1至5%SiO2,8至15%Al2O3,15至25%CaO,1.5至5%P2O5,4至8%Na2O,6至15%K2O,和3至8%MgO,以组合物总计为100重量%计。
在实施方式中,本公开内容提供了牙科制剂组合物,其中,合适的载剂包括选自下组的一种或多种成分:磨料,保湿剂(即,抗干燥剂,例如:丙三醇、山梨糖醇、木糖醇、1,2-丙二醇,聚乙二醇和类似化合物),香料,着色剂,抗菌剂,表面活性剂,增白剂和本领域已知的其他类似的合适成分,或其混合物。
在实施方式中,本公开内容提供了牙科制剂组合物,其中,合适的载剂包括选自下组的一种或多种形式:口香糖、糊料、粉末、牙膏、漱口水、膏药、茶、吸剂(sucker)、喷雾剂以及类似形式,或其混合物。
在实施方式中,本公开内容提供了再矿化组合物,其包含:上文所提及的生物活性玻璃组合物中的任意一种或其组合,以及任选的合适载剂(例如用于再矿化组合物的非水性载剂)。
在实施方式中,本公开内容提供了再矿化组合物,其包含上文所提及的生物活性玻璃组合物和任选的合适的载剂。
在实施方式中,本公开内容提供了牙本质超敏性或牙本质敏感性的治疗方法,其包括:
使得上文所提及的包含再矿化组合物的牙科制剂与牙科表面接触。
在实施方式中,与牙科制剂的接触具有相比于不含生物活性玻璃(即不存在生物活性玻璃)的牙科制剂基础配方而言更高的相对速率,对于暴露牙本质细管具有50至95%的堵塞。
在实施方式中,与牙科制剂的接触可以选自以下至少一种:用糊料制剂进行抛光,用液体制剂进行清洗,注射液体制剂,用复合物(例如,通常由粉末状生物活性玻璃和丙烯酸树脂制造)来填充牙齿,或其组合。
在实施方式中,牙科表面可以具有以下至少一种,例如:牙本质表面、牙本质细管,或其组合。
在实施方式中,本公开内容提供了牙科制剂,其包含:
有效量的生物活性玻璃组合物,其包含如下源:
2至70%B2O3,
2至16%Al2O3,
5至30%CaO,
1至6%P2O5,
1至20%Na2O;和
1至20%MgO,以组合物总计为100摩尔%计;以及有效量的合适的载剂,以生物活性玻璃和载剂总计100重量%计。源的摩尔%具有如下等价的重量百分比:1至60%B2O3,1至60%SiO2,2至20%Al2O3,5至25%CaO,1至10%P2O5,1至20%Na2O,1至25%K2O,和1至15%MgO,以组合物总计为100重量%计。
在实施方式中,牙科制剂不含二氧化硅(例如,SiO2源),以及不含无机钾盐(例如,K2O源)。
在一些实施方式中,本公开内容的优点在于以下几个方面,包括例如:所揭示的硼酸盐和硼硅酸盐玻璃组合物相比于含45S5的牙膏对于暴露牙本质细管具有明显更高的堵塞率,该结果证实了所揭示的生物活性玻璃对于治疗牙本质超敏性或牙本质敏感性具有优异的潜力;所揭示的生物活性玻璃组合物可以不含无机钾盐,以及所揭示的生物活性玻璃组合物和牙本质治疗制剂可以不含硅酸盐。和是含硅酸盐的生物活性玻璃。
在实施方式中,本公开内容提供了例如表1所列出的硼酸盐和硼硅酸盐生物活性玻璃组合物,其可以与哺乳动物唾液反应并且可以释放钙和磷酸根以形成羟基碳酸磷灰石,或者如果存在氟化物离子的话形成氟磷灰石(参见图2和3),在表面处通过形成涂抹层展现出细管堵塞和在牙本质细管内展现出细管堵塞,以及重建、强化和保护了牙齿结构。在磷灰石层中还存在痕量的镁沉积(图3)。正常的牙釉质和牙本质分别含有例如0.44和1.23重量%的镁。镁是许多酶的辅助因子,并且使得DNA和RNA的结构稳定化。镁对于牙齿发育和维护可能具有刺激作用。
表1:生物活性玻璃组合物,摩尔%
氟化物可以以前体的形式结合到玻璃组合物中,例如:氟化钠(NaF)、氟化亚锡(SnF2)、氟化钙(CaF2),以及类似的氟化物或其混合物。结合了氟化物的玻璃可以释放氟化物并在口腔流体中形成氟磷灰石。氟磷灰石相比于羟基碳酸磷灰石更抗酸溶解。
结合了氟化物的玻璃也可以被添加到非水性洁牙剂基质中,例如与其他生物活性玻璃组合。已知氟化物离子有助于形成磷灰石并且可以刺激成骨细胞分裂。
除了它们的再矿化牙膏效果之外,所揭示的玻璃组合物和制剂还可以是抗微生物的,该性质实现了例如预防龋齿、减少牙菌斑形成、控制牙龈炎、抑制呼吸异味以及类似的有益效果。所揭示的玻璃组合物和制剂还可以被结合到其他专业应用牙科产品中,例如,清洁和抛光糊料、牙清漆(varnishes)、再矿化填充材料以及类似制剂。
在实施方式中,本公开内容提供了再矿化组合物,其包含例如:
有效量(例如,0.1至10重量%)的生物活性玻璃组合物,其包含如下源:
2至70%B2O3,
1至60%SiO2,
2至16%Al2O3,
5至30%CaO,
1至6%P2O5,
1至20%Na2O,
1至20%K2O,以及
1至20%MgO,以组合物总计为100摩尔%计,并还任选地包含80至99.9重量%的合适的载剂(生物活性玻璃为0.1至20重量%),基于组合物与载剂的总重量。源的摩尔%具有如下等价的重量百分比:1至60%B2O3,1至60%SiO2,2至20%Al2O3,5至25%CaO,1至10%P2O5,1至20%Na2O,1至25%K2O,和1至15%MgO,以组合物总计为100重量%计。
参见附图,图1显示所揭示的生物活性组合物的化学作用和物理作用的假定方案。虽然不受限于理论,但是相信作用机制包括例如:生物活性玻璃颗粒与唾液或水反应,使得离子(例如,Na+、K+和类似离子)与H+发生交换并提升pH(100);钙和磷酸根沉淀为磷酸钙(110);以及磷酸钙或者氟化物(如果存在的话)结晶,在牙本质表面上或者牙本质细管内形成羟基碳酸磷灰石或氟磷灰石(120)。
图2A至2F显示测试牙本质盘在经过1周如下处理之后的SEM显微镜图:基础牙膏制剂(2A,2B);含45S5牙膏(2C,2D);或者含实施例1牙膏(2E,2F);以及浸入人造唾液中。对于基础牙膏处理,牙本质细管没有堵塞。在用含45S5的牙膏处理之后,牙本质细管被晶体状沉淀物部分堵塞。在用含实施例1的牙膏处理之后,大部分的牙本质细管和牙本质表面被晶体状沉淀物堵塞住。
图3A至3C显示牙本质沉积物在用含实施例1的牙膏处理1周之后的SEM-EDS分析。图3A显示的SEM具有两个选定点用于进一步分析(加了黑圈)。SEM-EDS分析显示形成在牙本质细管上和牙本质细管内的磷灰石是钙和磷酸根的沉淀以及少量痕量镁(参见图3B(点003)和3C(点004))。
材料和方法
将表1的每种玻璃组合物分开熔化并采用例如喷气研磨机研磨成1至10微米。
表1的每种经过研磨的玻璃组合物分开配制成牙科制剂,例如如表2所列。
对每种牙科制剂对于由人体臼齿制造的牙本质盘的遮蔽能力进行评估,如实施例9详细所示,即,将具有牙本质细管的盘暴露于牙科制剂,并与不含所揭示的生物活性玻璃的牙科制剂基础(对照样)进行对比。
表2:基础牙膏组合物和含示例性BG*的牙膏组合物
用于生产本公开内容的组合物的原材料和/或设备会引入某些不是故意添加的杂质或组分,并且它们会存在于最终的玻璃组合物中。此类材料会在所揭示的组合物中以少量存在,并且本文称作“杂物”。
所揭示的组合物通常会以痕量包含杂物。类似地,“不含铁”、“不含钠”、“不含锂”、“不含锆”、“不含碱土金属”、“不含重金属”或者类似描述表示组合物没有故意添加杂物,但是组合物仍然可能包含铁、钠、锂、锆、碱土金属或者重金属等,但是是近似痕量或者痕量。
除非另有说明,否则本文所引用的所有组分的浓度是以重量百分比(重量%)表示。
实施例
以下实施例示范了根据上文一般程序制造、使用和分析所揭示的组合物、制剂和方法。
实施例1
玻璃1,通过如下制备表1中的实施例1的组合物:将批料源材料以所示量单独混合,包括二氧化硅、硼酸、氧化铝、氧化钠、氧化钾、石灰石、氧化镁和磷酸钙。使用Turbula混合器,在塑料广口瓶中对批料源材料进行剧烈的混合。然后将它们转移到内部体积约为650cc的铂坩锅中。然后将坩埚装载到退火炉中,在250℃煅烧批料24小时。然后经煅烧的批料在1100至1300℃熔化6小时,然后将玻璃熔体倒到钢板上,以及在400至500℃退火。
实施例2至6
以与实施例1类似的方式制备玻璃2至6,不同之处在于,批料的组成或用量不同,并且如表1所示。
比较例7
比较例7,以与实施例1类似的方式制备比较例7的组合物,不同之处在于,在比较例玻璃中没有配料硼酸或氧化铝,参见例如US 20140186274(其提到了非水性基础组合物与生物活性玻璃的组合)。
实施例8
牙科制剂,通过如下方式制备表2的牙科制剂:首先向玻璃组合物添加丙三醇和PEG 400,然后分开加入制剂的剩余成分并用刮刀进行彻底混合。
实施例9
牙科制剂的评估,通过如下方式对表2的牙科制剂进行评估:通过合法方式从bforbones公司(bforbones.com)购得人体臼齿。使用Buehler低速水冷金刚石锯,在牙骨质-牙釉质接合面上方垂直于牙齿的长轴切割厚度为1mm的牙本质盘。用500目砂纸打磨30秒,在牙本质盘的两侧产生涂抹层。后续通过用6%柠檬酸处理3分钟然后用水冲洗以及37℃干燥,来去除该涂抹。将牙本质盘随机分成对照组或实验组,每组含有至少3个试样,其接收非水性牙膏基础制剂或含有5%45S5的牙膏;以及含有所揭示的玻璃组合物的牙膏,如表1和表2所列。使用牙膏和电动牙刷来刷牙质盘的两侧,每侧持续1分钟。然后,用蒸馏水冲洗试样以去除可见的痕量牙膏,然后储存在人造唾液中(1.5mMCaCl2,0.9mM KH2PO4,130mMKCl,和20mM HEPES,pH 7.4)。刷、冲洗和每个试样储存在人造唾液中的过程每天重复2次持续7天,然后试样在37℃干燥16小时,以及在SEM之前储存在RT。
已经参考各种具体实施方式和技术描述了本公开内容。但是,可以做出许多变化和改进而仍旧在本公开内容的范围内。
Claims (15)
1.一种牙科制剂,其包含:
有效量的生物活性玻璃组合物,其包含如下源:
2至70%B2O3,
1至60%SiO2,
2至16%Al2O3,
5至30%CaO,
1至6%P2O5,
1至20%Na2O,
1至20%K2O,以及
1至20%MgO,以组合物总计为100摩尔%计;以及
有效量的合适的载剂,以生物活性玻璃和载剂的总重量计。
2.如权利要求1所述的牙科制剂,其中,生物活性玻璃包含如下源:5至50%SiO2,以组合物总计为100摩尔%计,以及合适的载剂包含如下源:1至25重量%SiO2,相对于生物活性玻璃为超添加。
3.如权利要求1或2中任一项所述的牙科制剂,其还包括量为1至25摩尔%的氟化物离子源,相对于组合物为超添加。
4.如权利要求3所述的牙科制剂,其中,氟化物离子源选自NaF、SnF2、CaF2或者选定源的混合物。
5.如权利要求1-4中任一项所述的牙科制剂,其中,有效量的生物活性玻璃组合物是0.1至10重量%,以及有效量的合适的载剂是90至99.9重量%。
6.如权利要求1-5中任一项所述的牙科制剂,其中,生物活性玻璃组合物包含:
40至60%B2O3,
0.1至5%SiO2,
6至10%Al2O3,
15至25%CaO,
1.5至2%P2O5,
4至8%Na2O,
6至10%K2O,以及
6至10%MgO,以组合物总计为100摩尔%计。
7.如权利要求1-6中任一项所述的牙科制剂,其中,合适的载剂包括选自下组的一种或多种成分:磨料、保湿剂、香料、着色剂、抗菌剂、表面活性剂、增白剂、粘合剂,或其混合物。
8.如权利要求1-7中任一项所述的牙科制剂,其中,合适的载剂包括选自下组的一种或多种形式:口香糖、糊料、粉末、牙膏、漱口水、膏药、茶、吸剂、喷雾剂,或其混合物。
9.一种牙科制剂,其包含:
有效量的生物活性玻璃组合物,其包含如下源:
2至70%B2O3,
2至16%Al2O3,
5至30%CaO,
1至6%P2O5,
1至20%Na2O;和
1至20%MgO,以组合物总计为100摩尔%计;以及
有效量的合适的载剂,以生物活性玻璃和载剂的总重量为100重量%计。
10.一种再矿化组合物,其包含:
有效量的生物活性玻璃组合物,其包含如下源:
2至70%B2O3,
1至60%SiO2,
2至16%Al2O3,
5至30%CaO,
1至6%P2O5,
1至20%Na2O,
1至20%K2O,以及
1至20%MgO,以组合物总计为100摩尔%计。
11.如权利要求10所述的再矿化组合物,其还包含80至99.9重量%的合适的载剂,0.1至20重量%的生物活性玻璃,基于组合物和载剂的总重量计。
12.一种牙本质超敏性的治疗方法,其包括:
使得权利要求1-9中任一项所述的牙科制剂与牙科表面接触。
13.如权利要求12所述的方法,其中,与牙科制剂的接触具有相比于不含生物活性玻璃的牙科制剂基础而言更高的速率,对于暴露牙本质细管具有50至95%的堵塞。
14.如权利要求12或13所述的方法,其中,牙科制剂选自以下至少一种制剂:包含糊料制剂的抛光,包含液体制剂的清洗,包含液体制剂的可注射物,包含复合物的牙齿填料,或其组合。
15.如权利要求12-14中任一项所述的方法,其中,牙科表面具有以下至少一种:牙本质表面、牙本质细管,或其组合。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762591423P | 2017-11-28 | 2017-11-28 | |
| US62/591,423 | 2017-11-28 | ||
| PCT/US2018/062671 WO2019108556A1 (en) | 2017-11-28 | 2018-11-27 | Bioactive glass compositions and dentin hypersensitivity remediation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111405913A true CN111405913A (zh) | 2020-07-10 |
Family
ID=64746645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880075910.2A Pending CN111405913A (zh) | 2017-11-28 | 2018-11-27 | 生物活性玻璃组合物和牙本质超敏性修复 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11274059B2 (zh) |
| EP (1) | EP3717030A1 (zh) |
| CN (1) | CN111405913A (zh) |
| TW (1) | TW201929832A (zh) |
| WO (1) | WO2019108556A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3111638A1 (en) | 2018-09-05 | 2020-03-12 | Ir Scientific Inc. | Glass composition |
| TW202038887A (zh) | 2018-11-20 | 2020-11-01 | 美商康寧公司 | 生物活性硼酸鹽玻璃 |
| BR112022017655A2 (pt) * | 2020-03-03 | 2022-11-08 | Ir Scient Inc | Composição de vidro |
| US20230150864A1 (en) * | 2020-03-09 | 2023-05-18 | Ir Scientific Inc. | Glass composition |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997027148A1 (en) * | 1996-01-29 | 1997-07-31 | Usbiomaterials Corporation | Bioactive glass compositions and methods of treatment using bioactive glass |
| US20050142077A1 (en) * | 2001-12-12 | 2005-06-30 | Jose Zimmer | Usa of an antimicrobial glass ceramic for dental care and oral hygiene |
| US20070122356A1 (en) * | 2004-05-29 | 2007-05-31 | Schott Ag | Glass compositions as an antimicrobial additive for dental materials |
| US20120020898A1 (en) * | 2009-04-01 | 2012-01-26 | Colgate-Palmolive Company | Non-aqueous dentifrice composition with bioacceptable and bioactive glass and methods of use and manufacture thereof |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2532386A (en) | 1949-09-27 | 1950-12-05 | Corning Glass Works | Colored phosphate glass |
| NL232500A (zh) | 1957-10-22 | |||
| US2987339A (en) | 1960-01-27 | 1961-06-06 | Cullen Friestedt Company | Articulated lifter |
| BE618737A (zh) | 1961-06-12 | |||
| US3323888A (en) | 1964-03-17 | 1967-06-06 | Cataphote Corp | Method for manufacturing glass beads |
| US3778335A (en) | 1971-09-02 | 1973-12-11 | Corning Glass Works | Sodium aluminosilicate glass article strengthened by a surface compressive stress layer |
| US4126437A (en) | 1976-12-02 | 1978-11-21 | Xerox Corporation | Magnetic glass carrier materials |
| US4084972A (en) | 1977-01-07 | 1978-04-18 | Corning Glass Works | Glass-ceramics with metallic iron surfaces |
| US4083727A (en) | 1977-01-07 | 1978-04-11 | Corning Glass Works | Glass-ceramics with magnetic surface films |
| US4140645A (en) | 1978-06-12 | 1979-02-20 | Corning Glass Works | Glasses and glass-ceramics suitable for induction heating |
| GB2035290B (en) | 1978-11-24 | 1982-11-10 | Standard Telephones Cables Ltd | Glass compositions and cements incorporating such compositions |
| US4233169A (en) | 1979-04-13 | 1980-11-11 | Corning Glass Works | Porous magnetic glass structure |
| US4323056A (en) | 1980-05-19 | 1982-04-06 | Corning Glass Works | Radio frequency induced hyperthermia for tumor therapy |
| US4391646A (en) | 1982-02-25 | 1983-07-05 | Minnesota Mining And Manufacturing Company | Glass bubbles of increased collapse strength |
| JPS60210546A (ja) | 1984-04-02 | 1985-10-23 | Ngk Spark Plug Co Ltd | 歯冠用結晶化ガラス |
| GB8612387D0 (en) | 1986-05-21 | 1986-07-16 | Univ Sheffield | Glass ceramics |
| KR920001501B1 (ko) | 1987-09-01 | 1992-02-15 | 가부시기가이샤 히다찌세이사구쇼 | 블랙매트릭스 컬러브라운관 및 그 제조방법 |
| US4889707A (en) | 1988-01-29 | 1989-12-26 | The Curators Of The University Of Missouri | Composition and method for radiation synovectomy of arthritic joints |
| US5217928A (en) | 1988-08-24 | 1993-06-08 | Potters Industries, Inc. | Hollow glass spheres |
| US5196381A (en) | 1990-01-16 | 1993-03-23 | E. I. Du Pont De Nemours And Company | Metaphosphate glass composition |
| IT1240938B (it) | 1990-02-08 | 1993-12-27 | S.E.I.P.I. Societa' Esportazione Importazione Prodotti Industriali | Composizione vetrosa bioattiva per impianti ossei e prodotti ottenuti con tale composizione o che la comprendono |
| US5153070A (en) | 1990-08-01 | 1992-10-06 | Corning Incorporated | Coated refractory article and method |
| US5876452A (en) | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
| BR9206653A (pt) | 1992-08-20 | 1995-10-24 | Saint Gobain Isover | Método para produção de lá mineral e lá mineral produzida pelo mesmo |
| US5648124A (en) | 1993-07-09 | 1997-07-15 | Seradyn, Inc. | Process for preparing magnetically responsive microparticles |
| US5849816A (en) | 1994-08-01 | 1998-12-15 | Leonard Pearlstein | Method of making high performance superabsorbent material |
| DE4428851C2 (de) | 1994-08-04 | 2000-05-04 | Diagnostikforschung Inst | Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie |
| US6254981B1 (en) | 1995-11-02 | 2001-07-03 | Minnesota Mining & Manufacturing Company | Fused glassy particulates obtained by flame fusion |
| DE69614721T2 (de) | 1995-11-14 | 2002-07-04 | Corning Inc., Corning | Getrennte phasen aufweisende nichtkristalline opalgläser |
| US5674790A (en) | 1995-12-15 | 1997-10-07 | Corning Incorporated | Strengthening glass by ion exchange |
| US5735942A (en) | 1996-02-07 | 1998-04-07 | Usbiomaterials Corporation | Compositions containing bioactive glass and their use in treating tooth hypersensitivity |
| US6323549B1 (en) | 1996-08-29 | 2001-11-27 | L. Pierre deRochemont | Ceramic composite wiring structures for semiconductor devices and method of manufacture |
| US5834008A (en) | 1996-09-19 | 1998-11-10 | U.S. Biomaterials Corp. | Composition and method for acceleration of wound and burn healing |
| US6756060B1 (en) | 1996-09-19 | 2004-06-29 | Usbiomaterials Corp. | Anti-inflammatory and antimicrobial uses for bioactive glass compositions |
| AU4571097A (en) | 1996-10-09 | 1998-05-05 | Takeda Chemical Industries Ltd. | A method for producing a microparticle |
| WO1998047830A1 (en) | 1997-04-18 | 1998-10-29 | Minnesota Mining And Manufacturing Company | Transparent beads and their production method |
| US6280863B1 (en) | 1997-06-12 | 2001-08-28 | Ivoclar Ag | Translucent apatite glass ceramic |
| US6034014A (en) | 1997-08-04 | 2000-03-07 | Owens Corning Fiberglas Technology, Inc. | Glass fiber composition |
| GB9811661D0 (en) | 1998-06-01 | 1998-07-29 | Giltech Ltd | Compositions |
| US6802894B2 (en) | 1998-12-11 | 2004-10-12 | Jeneric/Pentron Incorporated | Lithium disilicate glass-ceramics |
| CA2343223C (en) | 1998-09-10 | 2014-08-12 | Usbiomaterials Corporation | Anti-inflammatory and antimicrobial uses for bioactive glass compositions |
| US6214471B1 (en) | 1998-11-03 | 2001-04-10 | Corning Incorporated | Glasses compatible with aluminum |
| JP2001010843A (ja) | 1999-04-30 | 2001-01-16 | Ohara Inc | 結晶性低融点ガラスおよび封着用組成物 |
| IT1313655B1 (it) | 1999-09-30 | 2002-09-09 | Techint Spa | Composizione di fibra di vetro. |
| US6328990B1 (en) | 1999-11-12 | 2001-12-11 | The Trustees Of The University Of Pennsylvania | Bioactive, degradable composite for tissue engineering |
| JP2001247333A (ja) | 1999-12-28 | 2001-09-11 | Ishizuka Glass Co Ltd | 抗菌性付与用ガラス組成物、抗菌性繊維、抗菌性撚糸及び抗菌性布状物 |
| US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
| JP4323707B2 (ja) | 2000-10-25 | 2009-09-02 | 富士通マイクロエレクトロニクス株式会社 | フラッシュメモリの欠陥管理方法 |
| US7597900B2 (en) | 2001-03-27 | 2009-10-06 | Schott Ag | Tissue abrasives |
| DE10141117A1 (de) | 2001-08-22 | 2003-03-13 | Schott Glas | Antimikrobielles Silicatglas und dessen Verwendung |
| US7166549B2 (en) | 2001-08-22 | 2007-01-23 | Schott Ag | Antimicrobial, anti-inflammatory, wound-healing and disinfecting glass and use thereof |
| WO2003018496A1 (de) | 2001-08-22 | 2003-03-06 | Schott Glas | Antimikrobielles, entzündungshemmendes, wundheilendes glaspulver und dessen verwendung |
| DE10203629A1 (de) | 2002-01-30 | 2003-07-31 | Ulrich Zimmermann | Vorrichtung und Verfahren zur Herstellung von Mikrokapseln sowie verbesserte Mikrokapsel |
| KR100797738B1 (ko) | 2002-11-15 | 2008-01-24 | 컬러 어섹스, 인코포레이티드 | 투명 컨실링 화장품 조성물 |
| US20050118236A1 (en) | 2002-12-03 | 2005-06-02 | Gentis Inc. | Bioactive, resorbable scaffolds for tissue engineering |
| WO2004076371A2 (de) | 2003-02-25 | 2004-09-10 | Schott Ag | Antimikrobiell wirkendes phosphatglas |
| JP4293806B2 (ja) | 2003-02-28 | 2009-07-08 | 石塚硝子株式会社 | 抗菌性付与用ガラス組成物、及びそれを用いた抗菌性高分子複合材料 |
| CA2519030A1 (en) | 2003-03-24 | 2004-10-07 | Exa Sa | A treatment composition |
| GB0310673D0 (en) | 2003-05-09 | 2003-06-11 | Givaudan Sa | Alginate matrix particles |
| JP2004359754A (ja) | 2003-06-03 | 2004-12-24 | Ishizuka Glass Co Ltd | 抗菌性樹脂組成物およびその成形品 |
| DE10336913C9 (de) | 2003-08-07 | 2019-02-21 | Ivoclar Vivadent Ag | Verwendung eines Lithiumsilicatmaterials |
| HU227595B1 (en) | 2003-08-07 | 2011-09-28 | Mta | Metal complexes of polygalacturonic acid and their production |
| US8444756B2 (en) | 2003-08-07 | 2013-05-21 | Ivoclar Vivadent Ag | Lithium silicate materials |
| FR2867075B1 (fr) | 2004-03-03 | 2006-07-14 | Ethypharm Sa | Procede de preparation de microspheres biodegradables calibrees |
| DE102004011520A1 (de) | 2004-03-08 | 2005-10-06 | Schott Ag | Antimikrobiell brechzahlangepasstes Phosphatglas |
| DE102004013455B3 (de) | 2004-03-18 | 2005-09-08 | Ivoclar Vivadent Ag | Apatitglaskeramik auf der Basis von silicatischen Oxyapatiten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| FR2873683B1 (fr) | 2004-07-27 | 2007-06-15 | Inst Nat Sciences Appliq | Bioverre poreux et procede de preparation |
| DE202004014053U1 (de) | 2004-09-07 | 2004-11-11 | Deep Colours! Gmbh | Tätowierfarbe |
| US20060127427A1 (en) | 2004-12-15 | 2006-06-15 | Vernice Joseph J | Surface coated abrasive material for cosmetic products |
| DE102005001078A1 (de) | 2005-01-08 | 2006-07-20 | Schott Ag | Glaspulver, insbesondere biologisch aktives Glaspulver und Verfahren zur Herstellung von Glaspulver, insbesondere biologisch aktivem Glaspulver |
| US9326995B2 (en) | 2005-04-04 | 2016-05-03 | The Regents Of The University Of California | Oxides for wound healing and body repair |
| US7989065B2 (en) | 2005-05-20 | 2011-08-02 | Seradyn, Inc. | Magnetically-responsive microparticles with improved response times |
| JP4226574B2 (ja) | 2005-06-27 | 2009-02-18 | 株式会社ノリタケカンパニーリミテド | 耐酸性を有するガラス組成物 |
| JP2007039269A (ja) | 2005-08-02 | 2007-02-15 | Asahi Glass Co Ltd | 電極被覆用ガラスおよびプラズマディスプレイ装置 |
| DE102005038070A1 (de) | 2005-08-10 | 2007-03-15 | Henkel Kgaa | Wasch- und Reinigungsmittel mit gut löslichen Kapseln |
| WO2007022264A2 (en) | 2005-08-15 | 2007-02-22 | The Regents Of The University Of California | Oxides for wound healing and body repair |
| KR100792456B1 (ko) | 2006-02-14 | 2008-01-10 | 엘지전자 주식회사 | 디스플레이 패널의 어드레싱 장치 및 그 방법 |
| KR101024417B1 (ko) | 2006-06-07 | 2011-03-23 | 가부시키가이샤 피노레 | 혼합 항균성 유리 |
| GB0612028D0 (en) | 2006-06-16 | 2006-07-26 | Imp Innovations Ltd | Bioactive glass |
| WO2008000888A2 (en) | 2006-06-28 | 2008-01-03 | Vivoxid Oy | Implant containing a source of oxygen |
| US20090324668A1 (en) | 2006-06-28 | 2009-12-31 | Ilkka Kangasniemi | Implant, its uses and methods for making it |
| US8288344B2 (en) | 2007-03-15 | 2012-10-16 | Musculoskeletal Transplant Foundation | Ceramic composition for filling bone defects |
| EP2217363B1 (en) | 2007-11-14 | 2018-09-19 | The University Of Queensland | Method and use of a device for preparing microparticles |
| US9241879B2 (en) | 2008-04-11 | 2016-01-26 | James R. Glidewell Dental Ceramics, Inc. | Lithium silicate glass ceramic for fabrication of dental appliances |
| CN101596326A (zh) | 2008-06-06 | 2009-12-09 | 华东理工大学 | 一种硼酸盐生物微晶玻璃及其制备方法和应用 |
| CN101407373B (zh) | 2008-11-18 | 2011-12-28 | 湖北顶盛科技发展有限公司 | 锶强化生物活性玻璃,其制备方法以及在洁牙产品中的应用 |
| EP2243749B1 (en) | 2009-04-23 | 2015-04-08 | PURAC Biochem BV | Resorbable and biocompatible fibre glass compositions and their uses |
| CN101704632B (zh) | 2009-11-30 | 2012-08-29 | 中国建材国际工程有限公司 | 一种高强度低密度空心玻璃微珠的制备方法 |
| US20110152057A1 (en) | 2009-12-21 | 2011-06-23 | Gang Qi | Hollow microspheres |
| US8173154B2 (en) | 2010-01-06 | 2012-05-08 | The Curators Of The University Of Missouri | Boron trioxide glass-based fibers and particles in dressings, sutures, surgical glue, and other wound care compositions |
| EP2386525A1 (en) | 2010-05-13 | 2011-11-16 | Universitat Politècnica de Catalunya | Nanostructured material comprising a biocompatible calcium phosphate glass, sol-gel process for its preparation and medical use thereof |
| US20160145567A1 (en) | 2010-05-27 | 2016-05-26 | Corning Incorporated | Cell culture article and methods thereof |
| GB201010758D0 (en) | 2010-06-25 | 2010-08-11 | Queen Mary & Westfield College | Bioactive glass composition |
| DE102010034083A1 (de) | 2010-08-12 | 2012-02-16 | Süd-Chemie AG | Magnetische Glaspartikel zum Einsatz in Biogasanlagen, Fermentations- und Separationsprozessen |
| US8883663B2 (en) | 2010-11-30 | 2014-11-11 | Corning Incorporated | Fusion formed and ion exchanged glass-ceramics |
| KR101262121B1 (ko) | 2010-12-27 | 2013-05-14 | 주식회사 하스 | 치아용 고강도 결정화유리의 제조방법 |
| CA2825016C (en) | 2011-01-24 | 2021-02-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nanoparticles for dermal and systemic delivery of drugs |
| PT105617A (pt) | 2011-04-05 | 2012-10-08 | Univ Aveiro | Composição de vidros bioactivos, sua utilização e respectivo método de obtenção |
| WO2012177617A1 (en) | 2011-06-20 | 2012-12-27 | The Procter & Gamble Company | Liquid cleaning and/or cleansing composition |
| US20120321567A1 (en) | 2011-06-20 | 2012-12-20 | Denis Alfred Gonzales | Liquid cleaning and/or cleansing composition |
| GB201113754D0 (en) | 2011-08-09 | 2011-09-21 | Glaxo Group Ltd | Composition |
| US20140000891A1 (en) | 2012-06-21 | 2014-01-02 | Self-Suspending Proppant Llc | Self-suspending proppants for hydraulic fracturing |
| PL2765977T3 (pl) | 2011-10-14 | 2016-06-30 | Ivoclar Vivadent Ag | Litowokrzemianowa ceramika szklana i szkło z tlenkiem jednowartościowego metalu |
| BR112014008579A2 (pt) | 2011-10-14 | 2017-04-18 | Ivoclar Vivadent Ag | vitrocerâmica e vidro de silicato de lítio com óxido de metal divalente |
| CN102430149A (zh) | 2011-11-18 | 2012-05-02 | 华东理工大学 | 一种硼磷酸盐玻璃纤维/壳聚糖复合材料 |
| KR101592133B1 (ko) | 2012-01-20 | 2016-02-05 | 스트라우만 홀딩 에이쥐 | 보철 부재 |
| CN102526797B (zh) | 2012-02-08 | 2013-10-30 | 同济大学 | 一种有规则孔分布的高强度生物玻璃骨支架的制备方法 |
| KR20130112433A (ko) | 2012-04-04 | 2013-10-14 | 주식회사 케이씨씨 | 유리 섬유 제조용 조성물 및 그로부터 제조된 생체용해성 유리 섬유 |
| JP5977442B2 (ja) | 2012-05-04 | 2016-08-24 | イフォクレール ヴィヴァデント アクチェンゲゼルシャフトIvoclar Vivadent AG | 二ケイ酸リチウムアパタイトガラスセラミック |
| PT2668967E (pt) | 2012-05-30 | 2014-07-30 | Skulle Implants Oy | Um implante |
| DE112013003596T5 (de) | 2012-07-19 | 2015-04-09 | Relypsa, Inc. | Zusammensetzungen, umfassend vernetzte kationbindende Polymere und deren Verwendung |
| US20140026916A1 (en) | 2012-07-25 | 2014-01-30 | College Of William And Mary | Method for Reducing Marine Pollution Using Polyhydroxyalkanoate Microbeads |
| US10064793B2 (en) | 2012-09-28 | 2018-09-04 | Stelo Technologies | Methods of making silver nanoparticles and their applications |
| WO2014095198A1 (en) | 2012-12-17 | 2014-06-26 | Unilever N.V. | Topical composition |
| US20140212469A1 (en) | 2013-01-28 | 2014-07-31 | Missouri University Of Science And Technology | Surface functional bioactive glass scaffold for bone regeneration |
| US20140219941A1 (en) | 2013-02-06 | 2014-08-07 | U.S. Cosmetic Corporation | Cosmetic powder coated with alginic acid and methods of making the same |
| CA2905728A1 (en) | 2013-03-14 | 2014-09-25 | Novabone Products, Llc | Sodium containing sol-gel derived bioactive glasses and uses thereof including hemostasis |
| EP2969985A4 (en) | 2013-03-14 | 2017-01-11 | Novabone Products, LLC | Compositions and methods for manufacturing sol-gel derived bioactive borophosphate glasses for medical applicatons |
| EP2792345B1 (de) | 2013-04-15 | 2019-10-09 | Ivoclar Vivadent AG | Lithiumsilikat-Glaskeramik und -Glas mit Gehalt an Cäsiumoxid |
| CN103172263B (zh) | 2013-04-16 | 2015-03-18 | 中国地质科学院 | 利用磷矿尾矿制备的生物微晶玻璃及其制备方法 |
| US9359244B2 (en) | 2013-05-21 | 2016-06-07 | Colorado School Of Mines | Alumina-rich glasses and methods for making the same |
| US9701573B2 (en) | 2013-09-06 | 2017-07-11 | Corning Incorporated | High strength glass-ceramics having lithium disilicate and beta-spodumene structures |
| US10117668B2 (en) | 2013-10-08 | 2018-11-06 | The Spectranetics Corporation | Balloon catheter with non-deployable stent having improved stability |
| KR101524482B1 (ko) | 2013-10-14 | 2015-06-02 | 주식회사 하스 | 지르코니아 상단에 안착되는 리튬 실리케이트 유리 또는 리튬 실리케이트 결정화 유리 및 이의 제조방법 |
| EP2868634B1 (de) | 2013-11-05 | 2021-07-07 | Ivoclar Vivadent AG | Lithiumdisilikat-Apatit-Glaskeramik mit Übergangsmetalloxid |
| CN106029174A (zh) | 2014-02-17 | 2016-10-12 | 宝洁公司 | 包含可生物降解的磨料颗粒的皮肤清洁组合物 |
| US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US9878940B2 (en) | 2014-02-21 | 2018-01-30 | Corning Incorporated | Low crystallinity glass-ceramics |
| CN103979796B (zh) | 2014-05-19 | 2016-08-24 | 白银金奇化工科技有限公司 | 一种高强度空心玻璃微珠及其制备方法 |
| WO2015187713A1 (en) | 2014-06-02 | 2015-12-10 | Antique Books, Inc. | Advanced proof of knowledge authentication |
| EP3151873B1 (en) | 2014-06-09 | 2020-03-11 | The Royal Institution for the Advancement of Learning / McGill University | Borate-glass biomaterials |
| US20170128174A1 (en) | 2014-06-23 | 2017-05-11 | 3M Innovative Properties Company | Process for producing a sintered lithium disilicate glass ceramic dental restoration and kit of parts |
| CN104108883B (zh) | 2014-08-11 | 2019-03-08 | 中国地质大学(北京) | 一种高强度二硅酸锂玻璃陶瓷及其制备方法 |
| KR101648175B1 (ko) | 2014-08-29 | 2016-08-16 | 주식회사 하스 | 고강도와 심미성을 지닌 크리스토벌라이트 결정상 함유 리튬 디실리케이트 결정화 유리 및 이의 제조방법 |
| EP3831788A1 (en) | 2014-10-08 | 2021-06-09 | Corning Incorporated | High strength glass-ceramics having petalite and lithium silicate structures |
| WO2016090359A2 (en) | 2014-12-05 | 2016-06-09 | Augusta University Research Institute, Inc. | Glass composites for tissue augmentation, biomedical and cosmetic applications |
| DE102015108171A1 (de) | 2015-05-22 | 2016-11-24 | Degudent Gmbh | Verfahren zur Erhöhung der Festigkeit von aus Lithiumsilikat-Glaskeramik bestehendem Formkörper |
| CN105236745A (zh) | 2015-08-27 | 2016-01-13 | 陕西科技大学 | 一种铁磁性Fe3O4纳米微晶玻璃及其制备方法 |
| CN105819697B (zh) | 2016-03-29 | 2019-03-01 | 中材科技股份有限公司 | 一种生物相容磷酸盐基连续玻璃纤维及由其制备的织物 |
| US10647962B2 (en) | 2016-05-27 | 2020-05-12 | Corning Incorporated | Bioactive aluminoborate glasses |
| US10059621B2 (en) | 2016-05-27 | 2018-08-28 | Corning Incorporated | Magnetizable glass ceramic composition and methods thereof |
| US10676713B2 (en) | 2016-05-27 | 2020-06-09 | Corning Incorporated | Bioactive borophosphate glasses |
| US20170342383A1 (en) | 2016-05-27 | 2017-11-30 | Corning Incorporated | Lithium disilicate glass-ceramic compositions and methods thereof |
| US20170340527A1 (en) | 2016-05-27 | 2017-11-30 | Corning Incorporated | Biodegradable microbeads |
| US10751367B2 (en) | 2016-05-27 | 2020-08-25 | Corning Incorporated | Bioactive glass microspheres |
| US10624994B2 (en) | 2017-08-30 | 2020-04-21 | King Abdulaziz University | Borate bioactive glass and methods of use for dentin and enamel restoration |
-
2018
- 2018-11-27 CN CN201880075910.2A patent/CN111405913A/zh active Pending
- 2018-11-27 WO PCT/US2018/062671 patent/WO2019108556A1/en not_active Ceased
- 2018-11-27 EP EP18822555.1A patent/EP3717030A1/en not_active Withdrawn
- 2018-11-28 TW TW107142442A patent/TW201929832A/zh unknown
- 2018-11-28 US US16/203,002 patent/US11274059B2/en active Active
-
2020
- 2020-11-06 US US17/091,573 patent/US20210130223A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997027148A1 (en) * | 1996-01-29 | 1997-07-31 | Usbiomaterials Corporation | Bioactive glass compositions and methods of treatment using bioactive glass |
| US20050142077A1 (en) * | 2001-12-12 | 2005-06-30 | Jose Zimmer | Usa of an antimicrobial glass ceramic for dental care and oral hygiene |
| US20070122356A1 (en) * | 2004-05-29 | 2007-05-31 | Schott Ag | Glass compositions as an antimicrobial additive for dental materials |
| US20120020898A1 (en) * | 2009-04-01 | 2012-01-26 | Colgate-Palmolive Company | Non-aqueous dentifrice composition with bioacceptable and bioactive glass and methods of use and manufacture thereof |
Non-Patent Citations (3)
| Title |
|---|
| G. JAGAN MOHINI等: "Studies on influence of aluminium ions on the bioactivity of B2O3-SiO2-P2O5-Na2O-CaO glass system by means of spectroscopic studies", 《APPLIED SURFACE SCIENCE》 * |
| KAREM NORIS-SUAREZ等: "Osteoblastic cells biomineralized on bioactive glass and glass-ceramics of the SiO2.Na2O.CaO.K2O.MgO.P2O5 system modified with Al2O3 and B2O3", 《JOURNAL OF CERAMIC PROCESSING RESEARCH》 * |
| RICARDO A. PIRES等: "The role of alumina in aluminoborosilicate glasses for use in glass-ionomer cementa", 《JOURNAL OF MATERIALS CHEMISTRY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US11274059B2 (en) | 2022-03-15 |
| EP3717030A1 (en) | 2020-10-07 |
| TW201929832A (zh) | 2019-08-01 |
| US20190161393A1 (en) | 2019-05-30 |
| US20210130223A1 (en) | 2021-05-06 |
| WO2019108556A1 (en) | 2019-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bakry et al. | The effect of a bioglass paste on enamel exposed to erosive challenge | |
| JP4557546B2 (ja) | デンタルケア、即ち、口腔の衛生のための抗菌性ガラスセラミックの使用 | |
| CN100506730C (zh) | 制备用于口腔疾病治疗的粒状、生物活性或可再吸收的生物硅酸盐的方法和组合物 | |
| CN111417603B (zh) | 生物活性硼酸盐玻璃及其方法 | |
| US20210130223A1 (en) | Bioactive glass compositions and dentin hypersensitivity remediation | |
| JP5731459B2 (ja) | 象牙質に関連する症状または疾患を予防または治療する組成物及び方法 | |
| EP2448638B1 (en) | Multicomponent glasses for use in personal care products | |
| US20070258916A1 (en) | Oral compositions for treating tooth hypersensitivity | |
| AU2009262061A1 (en) | Composition and method for enhancing flouride uptake using bioactive glass | |
| MXPA06006704A (es) | Composiciones y metodos para prevenir o reducir la paca y/o la gingivitis utilizando un dentifrico que contiene vidrio bioactivo. | |
| US20210378923A1 (en) | Novel composition | |
| AU2014327414A1 (en) | Dentifrice composition comprising sintered hydroxyapatite | |
| CN101677918A (zh) | 新用途 | |
| CN110997072B (zh) | 口腔护理组合物 | |
| CN111093604A (zh) | 口腔护理组合物 | |
| KR20210088531A (ko) | 유리 조성물 | |
| CN110859767A (zh) | 生物活性玻璃组合物及其制备方法和应用 | |
| JP7798779B2 (ja) | ガラス組成物 | |
| Rai et al. | NovaMin®: a promising antihypersensitivity agent | |
| CN115605445A (zh) | 玻璃组合物 | |
| Greenspan et al. | Bioactive Glass For Tooth Remineralization And Pain Desentization | |
| Greenspan | Pain-Desensitizing Dental Materials | |
| KR20040053647A (ko) | 구강 위생증진용 치약조성물 | |
| TW201440793A (zh) | 抗敏感牙膏 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |